283 results match your criteria: "New Mexico Cancer Center[Affiliation]"
Adv Radiat Oncol
December 2024
Department of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Purpose: For patients with hepatocellular carcinoma (HCC), stereotactic body radiation therapy (SBRT) has emerged as a locoregional treatment. Our purpose was to report outcomes in patients with HCC with Child-Pugh A (CP A) versus Child-Pugh B or C (CP B/C) liver dysfunction treated with SBRT.
Methods And Materials: A retrospective analysis of 80 patients with HCC, with a total of 94 tumors treated with SBRT, was conducted at a single institution.
JCO Glob Oncol
October 2024
The University of Kansas Comprehensive Cancer Center, Kansas City, KC.
Purpose: Women with pathogenic variants (PVs) in breast cancer (BC) and ovarian cancer (OC) associated genes are candidates for cancer risk-reducing strategies. Limited information is available regarding risk-reducing surgeries (RRS) among Hispanics. The aim of this study was to describe the uptake of RRS in an international real-world experience of Hispanic women referred for genetic cancer risk assessment (GCRA) and to identify factors affecting uptake.
View Article and Find Full Text PDFBackground: First classified in 2016, high-grade B-cell lymphoma (HGBCL) is a lymphoid neoplasm that is typically seen as an aggressive lymphoproliferative disorder (LPD). In most patients with HGBCL, various oncogene rearrangements present with advanced clinical features, such as central nervous system involvement. Patients with underlying autoimmune and rheumatologic conditions, such as rheumatoid arthritis, are at higher risk for developing LPDs, including highly aggressive subtypes of non-Hodgkin lymphomas such as HGBCL.
View Article and Find Full Text PDFLeukemia
April 2024
Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, FL, USA.
JCO Oncol Pract
April 2024
Division of Hematology/Oncology and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Purpose: Individuals diagnosed with cancer between 15 and 39 years (adolescent and young adult [AYA]) face unique vulnerability. Detail is lacking about care delivery for these patients, especially those with ALL. We address these knowledge gaps by describing AYA ALL care delivery details at National Cancer Institute Community Oncology Research Program (NCORP) (sub)affiliates by model of care.
View Article and Find Full Text PDFFed Pract
August 2023
Iowa City Veterans Affairs Healthcare System, Iowa.
Background: Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of several solid tumors. The use of ICIs is expected to rise as a growing number of indications are approved for their use by the US Food and Drug Administration and with the increasing number of patients with cancer. Unfortunately, ICIs are associated with the development of immune-mediated adverse reactions (IMARs).
View Article and Find Full Text PDFUrology
July 2023
University of Kansas, Kansas City, KS; New Mexico Cancer Center, Albuquerque, NM.
JNCI Cancer Spectr
August 2023
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: It is unclear whether genetic variants affecting vitamin D metabolism are associated with melanoma prognosis. Two functional missense variants in the vitamin D-binding protein gene (GC), rs7041 and rs4588, determine 3 common haplotypes, Gc1s, Gc1f, and Gc2, of which Gc1f may be associated with decreased all-cause death among melanoma patients based on results of a prior study, but the association of Gc1f with melanoma-specific death is unclear.
Methods: We investigated the association of the Gc1s, Gc1f, and Gc2 haplotypes with melanoma-specific and all-cause death among 4490 individuals with incident, invasive primary melanoma in 2 population-based studies using multivariable Cox-proportional hazards regression.
Purpose: CancerLinQ seeks to use data sharing technology to improve quality of care, improve health outcomes, and advance evidence-based research. Understanding the experiences and concerns of patients is vital to ensure its trustworthiness and success.
Methods: In a survey of 1,200 patients receiving care in four CancerLinQ-participating practices, we evaluated awareness and attitudes regarding participation in data sharing.
Haematologica
October 2023
Division of Oncology and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Tumour Virus Res
June 2023
The Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, Australia.
Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec'2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005-2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA).
View Article and Find Full Text PDFJAMA Netw Open
October 2022
Department of Medicine and Epidemiology, Columbia University, New York, New York.
Importance: Colony-stimulating factors are prescribed to patients undergoing chemotherapy to reduce the risk of febrile neutropenia. Research suggests that 55% to 95% of colony-stimulating factor prescribing is inconsistent with national guidelines.
Objective: To examine whether a guideline-based standing order for primary prophylactic colony-stimulating factors improves use and reduces the incidence of febrile neutropenia.
Toxicol Appl Pharmacol
December 2022
University of New Mexico Health Sciences Center, Community Environmental Health Program, College of Pharmacy, Albuquerque, NM, United States of America.
The Navajo Nation was heavily mined for uranium (U) during the cold-war leading to a legacy of >1100 abandoned U mining, milling and associated waste sites. The Navajo Birth Cohort Study was initiated to assess the effect of non-occupational legacy exposure to U during pregnancy on birth outcomes and child development. We report that 92% of babies with detectable urine U at birth were born from mothers who had urine U concentrations greater than national norms during pregnancy, indicative of prenatal exposure to U.
View Article and Find Full Text PDFPurpose: Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain. Within a pragmatic, randomized trial of a standing order entry (SOE) PP-CSF intervention, we conducted a substudy to evaluate the effectiveness of SOE for patients receiving intermediate-risk regimens.
Methods: TrACER was a cluster randomized trial where practices were randomized to usual care or a guideline-based SOE intervention.
Nat Genet
September 2022
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Asia Pac J Clin Oncol
February 2023
Department of Pulmonary, Critical Care and Sleep Medicine, All Indian Institute of Medical Sciences, New Delhi, India.
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality in India. To clarify rates of actionable mutations, and thereby identify opportunities to improve the delivery of best available care for a large volume of patients, a comprehensive review of available data is warranted.
Methods: Studies that reported prevalence of any actionable gene variant among adult Indian patients with advanced NSCLC were selected from three databases (PubMed, EMBASE, and Cochrane Library).
Purpose: CompLEEment-1 (NCT02941926) is a single-arm, open-label, multicentre phase IIIb study investigating the safety and efficacy of ribociclib plus letrozole (RIB + LET) in a large, diverse cohort who have not received prior endocrine therapy (ET) for advanced disease. We present an exploratory analysis of male patients.
Methods: Eligible patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), who had no prior ET and ≤ 1 line of prior chemotherapy for advanced disease, received RIB + LET.
Curr Oncol
November 2021
Department of Dermatology, University of North Carolina, Chapel Hill, NC 27599, USA.
Genome-wide association studies (GWAS) and candidate pathway studies have identified low-penetrant genetic variants associated with cutaneous melanoma. We investigated the association of melanoma-risk variants with primary melanoma tumor prognostic characteristics and melanoma-specific survival. The Genes, Environment, and Melanoma Study enrolled 3285 European origin participants with incident invasive primary melanoma.
View Article and Find Full Text PDFPurpose: Because of the negative impact of cancer treatment on female sexual function, effective treatments are warranted. The purpose of this multisite study was to evaluate the ability of two dose levels of extended-release bupropion, a dopaminergic agent, to improve sexual desire more than placebo at 9 weeks, measured by the desire subscale of the Female Sexual Function Index (FSFI), and to evaluate associated toxicities.
Methods: Postmenopausal women diagnosed with breast or gynecologic cancer and low baseline FSFI desire scores (< 3.
Cancer Prev Res (Phila)
November 2021
National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland.
In September 2020, the National Cancer Institute convened the first PARTNRS Workshop as an initiative to forge partnerships between oncologists, primary care professionals, and non-oncology specialists for promoting patient accrual into cancer prevention trials. This effort is aimed at bringing about more effective accrual methods to generate decisive outcomes in cancer prevention research. The workshop convened to inspire solutions to challenges encountered during the development and implementation of cancer prevention trials.
View Article and Find Full Text PDFCancer Epidemiol Biomarkers Prev
December 2021
Department of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico.
Background: Genome-wide association studies have reported that genetic variation at () is associated with risk of several chronic diseases including coronary artery disease, coronary artery calcification, myocardial infarction, and type 2 diabetes mellitus. is located at the locus, which encodes multiple melanoma tumor suppressors. We investigated the association of these variants with melanoma prognostic characteristics.
View Article and Find Full Text PDFJ Clin Oncol
November 2021
Ingrid A. Mayer, MD, MSCI, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN; Fengmin Zhao, PhD, Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Carlos L. Arteaga, MD, UT Southwestern Simmons Cancer Center, Dallas, TX; William F. Symmans, MD, MD Anderson Cancer Center, Houston, TX; Ben H. Park, MD, PhD, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN; Brian L. Burnette, MD, Cancer Research of Wisconsin and Northern Michigan (CROWN) NCORP, Green Bay, WI; Amye J. Tevaarwerk, MD, University of Wisconsin Carbone Cancer Center, Madison, WI; Sofia F. Garcia, PhD, Northwestern University, Evanston, IL; Karen L. Smith, MD, Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD; Della F. Makower, MD, Montefiore Medical Center, Bronx, NY; Margaret Block, MD, Alegent Health Bergan Mercy Medical Center, Omaha, NE; Kimberly A. Morley, MD, Saint Joseph Mercy Hospital, Ann Arbor, MI; Chirag R. Jani, MD, Phoebe Putney Memorial Hospital, Albany, GA; Craig Mescher, MD, Metro-Minnesota Community Oncology Research Consortium, St Louis Park, MN; Shabana J. Dewani, MD, Columbus Oncology and Hematology Associates Inc, Columbus, OH; Bernard Tawfik, MD, University of New Mexico Cancer Center, Albuquerque, NM; Lisa E. Flaum, MD, Northwestern University, Evanston, IL; Erica L. Mayer, MD, Dana-Farber Cancer Institute, Boston, MA; William M. Sikov, MD, Women and Infants Hospital of Rhode Island, Providence, RI; Eve T. Rodler, MD, University of California, Davis, Davis, CA; Lynne I. Wagner, PhD, Wake Forest University Health Sciences, Winston-Salem, NC; Angela M. DeMichele, MD, University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA; Joseph A. Sparano, MD, Montefiore Medical Center, Bronx, NY; Antonio C. Wolff, MD, Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD; and Kathy D. Miller, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
Prev Med
December 2021
Center for HPV Prevention, New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.. Electronic address:
Failure to follow-up women after abnormal cervical screening could lead to cervical cancers, yet little is known about adherence to recommended follow-up after abnormal co-testing [cytology and high-risk human papillomavirus (hrHPV) testing]. We documented clinical management following cervical screening by co-testing in a diverse population-based setting. A statewide surveillance program for cervical screening, diagnosis, and treatment was used to investigate all cytology, hrHPV and biopsy reports in the state of New Mexico from January 2015 through August 2019.
View Article and Find Full Text PDF